Diferencia entre revisiones de «Herpes Simplex Virus-2»
(→Workup) |
|||
| Línea 26: | Línea 26: | ||
*[[Proctitis]] | *[[Proctitis]] | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Derm]] | [[Category:Derm]] | ||
[[Category:GU]] | [[Category:GU]] | ||
[[Category:ID]] | [[Category:ID]] | ||
Revisión del 06:32 3 feb 2016
Background
Clinical Features
- multiple painful lesions
- no buboes (occ shoddy LAD)
- more common in African Americans
- starts with small clumps of blisters that may have been preceded with local pain, tingling, itching, and burning
- +/- constiutional symptoms (fever, fatigue, myalgias, headaches)
Differential Diagnosis
Diagnosis
Management
Initial Episode[1][2]
- Acyclovir 400mg PO q8hrs x 7-10 days or 200mg PO 5x/day x 7-10 days OR
- Valacyclovir 1g PO q12hrs x 7-10 days OR
- Famciclovir 250mg PO q8hrs x 7-10 days
Recurrence[1]
- Acyclovir 400mg PO q8hrs x 5 days or 800mg PO q12hrs x 5 days or 800mg PO q8hrs x 2 days OR
- Valacyclovir 500mg PO q12hrs x 3 days or 1g PO qd x 5 days OR
- Famciclovir 125mg PO q12hrs for 5 days or 1g PO q12hrs for 1 day or 500mg PO once then 250mg PO q12hrs for 2 days
Suppressive Therapy[1]
- Acyclovir 400mg PO q12hrs daily OR
- Famciclovir 250mg PO q12hrs daily OR
- Valacyclovir 500mg-1g PO daily (500mg may be less effective)
Disposition
- Generally outpatient
See Also
References
- ↑ 1.0 1.1 1.2 Workoski KA and Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen and Reports. 2015; 64(3):1-140.
- ↑ https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf